GSK And Xenoport Announce Submission Of New Drug Application Requesting FDA Approval Of Solzira™ For Restless Legs Syndrome GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira™ (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Source: www.medicalnewstoday.comEcominds Offers Pots Of Cash To Local Environmental Projects, UK Mental
health charity Mind will celebrate the launch of Ecominds, its new multi-million pound grant giving scheme, by holding a garden party at Meanwhile Wildlife Gardens in London today (Thursday 18 September).
Source: www.medicalnewstoday.com
# posted by Network @ 10:00 AM
